Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Subprotocol of DAY101 Monotherapy for Patients With Recurrent, Progressive, or Refractory Solid Tumors With MAPK Pathway Aberrations

NCT04985604 is registered in ClinicalTrials.gov with Day One Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT04985604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04985604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Subprotocol of DAY101 Monotherapy for Patients With Recurrent, Progressive, or Refractory Solid Tumors With MAPK Pathway Aberrations
Lead sponsor
Day One Biopharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 15, 2021
Completion date
July 8, 2024
Enrollment
23 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, bladder urothelial carcinoma, braf fusion, braf gene fusion, colorectal cancer, craf fusion, craf gene amplification, craf gene fusion, map kinase family gene mutation, melanoma, non small cell lung cancer, non-small cell adenocarcinoma, pancreatic acinar carcinoma, pilocytic astrocytoma, pilocytic astrocytoma, adult, raf mutation, raf1 fusion, raf1 gene amplification, raf1 gene fusion, solid tumor, spitzoid malignant melanoma, spitzoid melanoma, thyroid cancer, papillary